14
August
2009
August
2009
Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile With Subcutaneous Administration
Palatin Technologies, Inc. (NYSE Amex: PTN) announced the completion of a Phase 1 clinical trial of subcutaneously administered bremelanotide, its melanocortin agonist drug candidate for treatment of male erectile dysfunction (ED) and female sexual dysfunction (FSD). The results demonstrate that with subcutaneous administration consistent therapeutic blood plasma levels can be obtained without blood pressure side effects.